1MU2 image
Deposition Date 2002-09-23
Release Date 2002-10-30
Last Version Date 2023-10-25
Entry Detail
PDB ID:
1MU2
Keywords:
Title:
CRYSTAL STRUCTURE OF HIV-2 REVERSE TRANSCRIPTASE
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.35 Å
R-Value Free:
0.24
R-Value Work:
0.19
Space Group:
P 21 21 21
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:HIV-2 RT
Gene (Uniprot):gag-pol
Mutagens:R286S
Chain IDs:A
Chain Length:555
Number of Molecules:1
Biological Source:Human immunodeficiency virus 2
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:HIV-2 RT
Gene (Uniprot):gag-pol
Mutagens:R286S
Chain IDs:B
Chain Length:426
Number of Molecules:1
Biological Source:Human immunodeficiency virus 2
Primary Citation
Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors
Proc.Natl.Acad.Sci.USA 99 14410 14415 (2002)
PMID: 12386343 DOI: 10.1073/pnas.222366699

Abstact

The HIV-2 serotype of HIV is a cause of disease in parts of the West African population, and there is evidence for its spread to Europe and Asia. HIV-2 reverse transcriptase (RT) demonstrates an intrinsic resistance to non-nucleoside RT inhibitors (NNRTIs), one of two classes of anti-AIDS drugs that target the viral RT. We report the crystal structure of HIV-2 RT to 2.35 A resolution, which reveals molecular details of the resistance to NNRTIs. HIV-2 RT has a similar overall fold to HIV-1 RT but has structural differences within the "NNRTI pocket" at both conserved and nonconserved residues. The structure points to the role of sequence differences that can give rise to unfavorable inhibitor contacts or destabilization of part of the binding pocket at positions 101, 106, 138, 181, 188, and 190. We also present evidence that the conformation of Ile-181 compared with the HIV-1 Tyr-181 could be a significant contributory factor to this inherent drug resistance of HIV-2 to NNRTIs. The availability of a refined structure of HIV-2 RT will provide a stimulus for the structure-based design of novel non-nucleoside inhibitors that could be used against HIV-2 infection.

Legend

Protein

Chemical

Disease

Primary Citation of related structures